

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

**(1) DELAY IN PUBLICATION OF
AUDITED ANNUAL RESULTS AND ANNUAL REPORT; AND
(2) NOTICE OF BOARD MEETING**

This announcement is made by Wai Chun Bio-Technology Limited (the “**Company**”), together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 20 September 2022 in relation to a meeting of the board of directors (the “**Board**”) will be held on 30 September 2022, among other matters, approve the audited annual results of the Company and its subsidiaries for the eighteen months ended 30 June 2022 (the “**2022 Audited Annual Results**”) and its publication.

(1) DELAY IN PUBLICATION OF AUDITED ANNUAL RESULTS

Pursuant to Rules 13.49(1) of the Listing Rules, the Company is required to publish in accordance with rule 2.07C its preliminary results in respect of each financial year not later than three months after the end of the financial year.

Due to the outbreak of COVID-19 in Shandong Province since late August 2022, the government of Changle County in Shandong Province implemented stringent travel and quarantine restrictions to find out the close contacts. The two major operating subsidiaries of the Group, Weifang Century-Light Biology Science Company Limited and Weifang Jia You You Zhi Company Limited are located in Changle County of Shandong Province, therefore the stringent travel and quarantine restrictions adversely affected the conduct of audit procedures, including physical inspection of property, plant and equipment in Shandong Province of the Group, face-to-face collaborative enquiry with key management personnel of the Group and all other relevant third parties, and vouching of supporting documents of the Group.

The Board anticipated the 2022 Audited Annual Results can not be published on or before 30 September 2022 in accordance with Rules 13.49(1). The Company expects to publish the 2022 Audited Annual Results as soon as possible after the auditors have completed the relevant audit procedures.

In order to keep the Shareholders and potential investors informed of the Group's business operation and financial position, the Board will publish the unaudited annual results for the eighteen months ended 30 June 2022 (the “**2022 Unaudited Annual Results**”) on 30 September 2022 based on the management accounts of the Group for the eighteen months ended 30 June 2022. The 2022 Unaudited Annual Results will be reviewed by the Audit Committee of the Company.

(2) ESTIMATED TIME FOR PUBLISHING THE AUDITED ANNUAL RESULTS AND ANNUAL REPORT

In view of the above circumstances, the Company expects to publish the 2022 Audited Annual Results on or before 31 October 2022, and despatch the annual report on or before 15 November 2022. Further announcements will be published by the Company to update the above matters in due course, in accordance with the Listing Rules and Securities and Futures Ordinance.

(3) CHANGE THE DATE OF BOARD MEETING

The Board announces that due to the delay in publication of the 2022 Audited Annual Results, the board meeting for the purpose of considering and approving, among others, the 2022 Audited Annual Results will be postponed and the Company will publish further announcement to inform its shareholders on the date of the relevant Board meeting as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Wai Chun Bio-Technology Limited
Chan Cheuk Ho
Executive Director

Hong Kong, 22 September 2022

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Chan Cheuk Ho and two independent non-executive Directors, namely Mr. Wan Bo and Mr. Hau Pak Man.